FTSE 100 dividend stock GlaxoSmithKline isn’t the only healthcare star that could help you retire rich

Royston Wild explains why GlaxoSmithKline plc (LON: GSK) is just one London-quoted healthcare stock that could make you rich.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I would consider GlaxoSmithKline (LSE: GSK) to be a top-class pick for investors to make a fortune. And not only on account of its monster 5.1% dividend yield.

As my colleague Edward Sheldon recently commented, the world is set to experience a boom in the number of so-called silver surfers in the coming decades, a surge in the number of citizens over the age of 60. With this comes rising healthcare demand, naturally, and this is a phenomenon that GlaxoSmithKline, with its broad range of treatments, is in prime position to exploit.

This isn’t the only reason to pile in to GlaxoSmithKline today. Investors in the pharmaceuticals arena need to be prepared for long, frustrating and often extremely-expensive product launch delays in the event of poor testing data and/or the thumbs-down from regulators. The FTSE 100 firm has a great track record of getting its products to market relatively quickly, however, a critical quality in recent years as the business has suffered from crushing patent losses such as that of Advair.

Hospitals hero

Investors still concerned about the unpredictability surrounding drugs pipelines may be tempted to buy in to fellow Footsie share NMC Health (LSE: NMC) instead.

Like GlaxoSmithKline, the private healthcare provider is also in great shape to ride the boom of ageing citizens. It is, however, involved in offering a range of medical services from gynaecology and obstetrics though to drugs dispensing, although it is probably more famous for its hospital network which spans the United Arab Emirates.

In total NMC can actually boast a network of 185 facilities in 17 countries, a footprint that has been helped by rampant acquisition activity. It’s well placed to benefit from citizens’ booming wealth in the Emirates, but it is not content to rest on the exceptional emerging market revenues opportunities that it has. More specifically, it has stated its intention in recent times to get a slice of the fast-growing fertility clinic market and is looking to open a swathe of such clinics across Europe.

A pet pick

Looking at the business of healthcare though a different lens, Animalcare (LSE: ANCR) is a very-promising pharmaceuticals play focused on helping our sick four-legged friends. The business of providing medicines to both agricultural and companion animals is becoming increasingly large, and thanks to its exceptional product ranges things look exceptionally healthy for the AIM-quoted firm.

Animalcare’s operations have been given a huge boost following the acquisition of Ecuphar last year, a move that has boosted its geographical reach as well as its operational clout. The rationale of the move was underlined by news released this week that revenues from pet products jumped almost 70% year-on-year between January and June, to £23.6m.

And investors should be encouraged by the company’s vow to supercharge its position in the high-margin veterinary pharmaceuticals products arena. Its declining share price suggests that the market remains unconvinced right now, but I reckon the earnings outlook for the business remains extremely exciting.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Are Warren Buffett and Michael Burry preparing for a stock market crash?

Warren Buffett has been holding off investing and Michael Burry has been selling stocks. Is this a sign that they’re…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

3 reasons why Rolls-Royce shares could be a big winner in 2023 

Rolls-Royce shares are up 12% since May 2022. And I think recent developments could propel the engineering firm to new…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Rolls-Royce’s share price is recovering! Time to buy?

Rolls-Royce's share price has clawed back ground after plunging earlier this month. Should I buy the FTSE 100 firm on…

Read more »

Happy couple showing relief at news
Investing Articles

I’d buy this FTSE stock to boost my passive income stream for years to come!

Jabran Khan is looking for stocks to boost his passive income and dissects one FTSE stock he currently likes.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Darktrace share price soars 20% on takeover news! Who could be next?

Takeover talks are in the air. Our writer considers several potential takeover targets following the Darktrace share price jump.

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Here’s 1 growth stock I like for long-term growth and returns!

Jabran Khan delves deeper into a growth stock he is considering for his holdings to boost returns now and in…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

This FTSE 100 stock could be perfect for dividends and growth!

This Fool is looking to boost his passive income stream with stocks that have growth prospects. Here’s one FTSE 100…

Read more »

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Should I be buying IAG shares today?

Since IAG reported its H1 results, its share price has been stagnant. So, should I buy its stock now to…

Read more »